Targeted transgene expression in rat brain using lentiviral vectors
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Direct gene transfer to the adult brain is dependent on vectors that transduce non‐dividing cells, such as lentiviral vectors. Another aspect of the development of gene therapy to the brain is the need for cell‐specific transgene expression. Expression from vesicular stomatitis virus G‐protein (VSV‐G) pseudotyped lentiviral vectors has been reported to be mainly neuron specific in the brain. We constructed cell‐specific lentiviral vectors using the neuron‐specific enolase (rNSE) or the glial fibrillary acidic protein (hGFAP) promoters and compared them to the ubiquitous human cytomegalovirus promoter (hCMV), a hybrid CMV/β‐actin promoter (CAG) and the promoter for human elongation factor 1α (EF1α). Our results showed that the hGFAP promoter was expressed only in glial cells, whereas rNSE was purely neuron specific, showing that VSV‐G is pantropic in the rat striatum. We conclude that the VSV‐G allows transduction of both glial and neuronal cells and the promoter dictates in what cell type the transgene will be expressed. The expression of transgenes exclusively in astrocytes would allow for local delivery of secreted transgene products, such as glial cell line‐derived neurotrophic factor (GDNF), circumventing the anterograde transport that may induce unwanted side effects. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 3×
“…(VSV-G) (Sanders, 2002), which is used regularly to pseudotype these vectors (pseudotype refers to the use of an envelope protein derived from a virus different from vector virus) to achieve a broad transduction spectrum and allow for concentration using ultracentrifugation (Zufferey et al., 1997).”
MethodInfluentialNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 2×
“This is in line with previous reports where VSV-G pseudotyped lentiviral vectors were found to transduce mainly neurons when using ubiquitous promoters (hCMV and mPGK; Naldini et al., 1996; Blomer et al., 1997; Deglon et al., 2000).”
ResultLentiviral vectors for enhanced gene expression in human hematopoietic cells
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0190 · Cited by 217 · cited 1×
“Promoter choice in this study in the case of CAG, CMV, and EF1 was based on work carried out by several research groups, which have found these promoters particularly interesting for gene transfer when using lentiviral vectors (for example, see Ramezani et al., 2000).”
BackgroundEnglund, U., Fricker-Gates, R. A., Lundberg, C., Björklund, A., & Wictorin, K. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7750 · Cited by 187 · cited 1×
“Lentiviral vectors also hold great promise as experimental vectors in several settings in the brain, including stem cell research and development of transgenic animal models (de Almeida et al., 2002; Englund et al., 2002; Lo Bianco et al., 2002).”
BackgroundSelf-citation
Cited by
Optogenetics in neural systems
Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M., & Deisseroth, K. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.004 · Cited by 1,881
Regulatable gene expression systems for gene therapy applications: progress and future challenges
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., Soffer, E. B., Mondkar, S., King, G. D., Hu, J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.022 · Cited by 283
“Lentiviral vectors are members of the retrovirus family that can transduce nondividing as well as dividing cells [35-39].”
BackgroundA Student’s Guide to Neural Circuit Tracing
Saleeba, C., Dempsey, B., Le, S., Goodchild, A., & McMullan, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00897 · Cited by 153
Expression Specificity of GFAP Transgenes
Su, M., Hu, H., Lee, Y., D’Azzo, A., Messing, A., & Brenner, M. (2004) · Neurochemical Research · doi:10.1007/s11064-004-6881-1 · Cited by 124
Nieuwenhuis, B., Haenzi, B., Hilton, S., Carnicer-Lombarte, A., Hobo, B., Verhaagen, J., & Fawcett, J. W. (2021) · Gene Therapy · doi:10.1038/s41434-020-0169-1 · Cited by 114
Methods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
Rahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101
Åkerblom, M., Sachdeva, R., Quintino, L., Wettergren, E. E., Chapman, K. Z., Manfre, G., Lindvall, O., Lundberg, C., & Jakobsson, J. (2013) · Nature Communications · doi:10.1038/ncomms2801 · Cited by 85
Self-citationClinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery
Joshi, C. R., Labhasetwar, V., & Ghorpade, A. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9724-3 · Cited by 55
“On the other hand, an earlier study demonstrated VSV-G-LV-mediated exclusive neuronal or astrocyte transduction using cell-specific promoter restriction rather than pseudotyping (Jakobsson et al. 2003).”
In vivo optogenetic control of striatal and thalamic neurons in non-human primates
Galvan, A., Hu, X., Smith, Y., & Wichmann, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050808 · Cited by 45
“To maximize our chances of finding opsin expression, we used EF1a a ubiquitous promoter [53], that demonstrates mainly neuronal preference in the brain when used in combination with lentiviral vectors [54].”
MethodIntramuscular Delivery of Gene Therapy for Targeting the Nervous System
Tosolini, A. P., & Sleigh, J. N. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00129 · Cited by 32
An Improved Tet-On System for Gene Expression in Neurons Delivered by a Single Lentiviral Vector
Tian, X., Wang, G., Xu, Y., Wang, P., Chen, S., Yang, H., Gao, F., Xu, A., Cao, F., Jin, X., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.018 · Cited by 21
“…a preference for neuronal cell transduction (Blomer et al., 1997; Kordower et al., 1999), more recent experiments have demonstrated that this neuronal tropism might be due to the internal promoters used in these studies having low activity in glial cells in vivo ( Jakobsson et al., 2003, 2004).”
BackgroundOn the development of optical peripheral nerve interfaces
Anderson, H., & Weir, R. F. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.245461 · Cited by 14
“Lentiviral vectors are often pseudotyped using the vesicular stomatis virus glycoprotein (VSVg), which allows for wide tropism, including in glia and neurons (Jakobsson et al., 2003).”
Background
Metadata
- Authors
- Jakobsson, J., Ericson, C., Jansson, M., Björk, E., & Lundberg, C.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2003-08
- Volume
- 73
- Issue
- 6
- Pages
- 876-885
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2041691400
- Cited by
- 164
- References
- 5
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.